Multinational pharmaceutical company Abbott has signed an agreement with Sweden’s Oasmia to market a canine cancer treatment. The product, Paccal Vet, contains the active ingredient paclitaxel, which is well established as a treatment for cancer in humans. Oasmia has reformulated it for use ...
Please Login to read the full article.
